Insights with Impact: Empowering Laboratories with a Decentralized MSK Solution for CGP​

 

Pierluigi Iapicca - Product Manager, Solid Tumors, SOPHiA GENETICS​

Dr. Kojo Elenitoba-Johnson -Chair, Department of Pathology ​and Laboratory Medicine, MSKCC

​Comprehensive genomic profiling (CGP) using a matched tumor-normal approach can help improve somatic detection rate and streamline interpretation.​

​MSK-IMPACT® powered with SOPHiA DDM™ is a CGP solution that leverages matched tumor-normal sequencing to filter germline variants and may also identify clonal hematopoietic variants, revealing mutations of true somatic origin. The end-to-end application combines the clinical expertise of Memorial Sloan Kettering Cancer Center (MSK) with the robust analytics of SOPHiA DDM™. ​

Join us and MSK to:​

  • Discover the clinical utility of MSK-IMPACT® at MSK.​

  • Explore the decentralized workflow, robust technology, and analytical performance of MSK-IMPACT® powered with SOPHiA DDM™.​

​

Register here for the event